title: [Proteome-based diagnostic and prognostic biomarkers of prostate cancer].
abstract: BACKGROUND
  Due to comprehensive PSA screening, the incidence for prostate cancer (PCa) is rising. Therefore, there is an urgent need for improved PCa diagnostics and prognostic tools to differentiate between insignificant and aggressive, fast growing tumors.
  
  
  METHODS
  With the proteome-based method presented here, we were able to distinguish PCa from BPH, chronic prostatitis and healthy controls with 83 % sensitivity and 67 % specificity. Furthermore, the methods discerned advanced PCa from local, organ-confined PCa in a group of patients with gleason score 7 (80 % sensitivity, 82 % specificity).
  
  
  RESULTS
  Our proteomic approach is based on the analysis of low molecular weight polypeptides, identified as the endpoint of the naturally occuring liquefaction cascade in seminal plasma. For the first time using seminal plasma as a source, we analysed a complex network of interacting proteases and specific inhibitors, reflecting tumor biology specificity. Our diagnostic and prognostic tool is robust and easy to handle, and therefore it is well suitable for the laboratory and medical practice.
authors.affiliation: Department für Operative Medizin, Klinik und Poliklinik für Urologie, Universitätsklinikum Leipzig AöR, Liebigstraße 20, 04103, Leipzig, Deutschland, jochen.neuhaus@medizin.uni-leipzig.de.
authors.forename: J
authors.initials: J
authors.lastname: Neuhaus
authors.forename: E
authors.initials: E
authors.lastname: Schiffer
authors.forename: J
authors.initials: J
authors.lastname: Siwy
authors.forename: F
authors.initials: F
authors.lastname: Mannello
authors.forename: L-C
authors.initials: LC
authors.lastname: Horn
authors.forename: J-U
authors.initials: JU
authors.lastname: Stolzenburg
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D015995:Prevalence; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000453:epidemiology; D020543:Proteome / Q000032:analysis*; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D020543:Proteome
references.citation: Mass Spectrom Rev. 2005 Nov-Dec;24(6):959-77
references.pmid: 15747373
references.citation: N Engl J Med. 2005 Sep 22;353(12):1224-35
references.pmid: 16177248
references.citation: Radiol Clin North Am. 2000 Jan;38(1):49-58
references.pmid: 10664666
references.citation: PLoS One. 2013 Jun 24;8(6):e67514
references.pmid: 23826311
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Proteomics. 2009 Aug 20;72(6):907-17
references.pmid: 19457353
references.citation: N Engl J Med. 2004 May 27;350(22):2239-46
references.pmid: 15163773
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Curr Cancer Drug Targets. 2005 Jun;5(4):285-98
references.pmid: 15975049
references.citation: BJU Int. 2008 Mar;101(6):675-83
references.pmid: 17941930
references.citation: Mol Diagn. 2004;8(2):77-85
references.pmid: 15527321
references.citation: J Urol. 2004 Oct;172(4 Pt 1):1302-5
references.pmid: 15371828
references.citation: World J Urol. 2007 Dec;25(6):557-62
references.pmid: 17690889
references.citation: Proteomics Clin Appl. 2008 Apr 1;2(4):543-555
references.pmid: 20559448
references.citation: Proteomics Clin Appl. 2008 Mar 7;2(4):556-570
references.pmid: 19759844
references.citation: J Proteome Res. 2009 Jan;8(1):335-45
references.pmid: 19053529
references.citation: Lancet Oncol. 2006 Mar;7(3):230-40
references.pmid: 16510332
references.citation: Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720
references.pmid: 23440794
references.citation: Mol Cell Proteomics. 2012 Dec;11(12):1870-84
references.pmid: 22986220
references.citation: Int J Urol. 2012 Feb;19(2):118-25
references.pmid: 22103570